

**Stanley C. Jordan, MD, FASN, FAST**

*Director, Nephrology & Transplant Immunology*

*Medical Director, Kidney Transplant Program*

Cedars-Sinai Medical Center

Los Angeles, CA

Stanley C. Jordan, MD, FASN, FAST, is the director of Nephrology and Transplant Immunology and the medical director of the Kidney Transplant Program at Cedars-Sinai Medical Center in Los Angeles, CA. Dr Jordan received his medical degree from University of North Carolina in Chapel Hill, NC. He then completed his internship, residency, and fellowship at the University of California - Los Angeles. Dr Jordan is board certified in pediatrics, pediatric nephrology, and diagnostic laboratory immunology.

Dr Jordan has focused his research on the immunology of antibody rejection and the development of novel immune modulatory therapies. His work is funded by the NIH and grants from biotechnology firms aimed at developing novel therapies in transplant medicine. Dr Jordan continues to be dedicated to improving transplantation rates for highly human leukocyte antigen (HLA) and ABO blood group incompatible transplant recipients. His team developed the first desensitization protocol to reduce harmful anti-HLA antibodies. This evolved into 3 NIH funded UO1 Controlled Clinical Trials, of which he was the PI. Dr Jordan and his team subsequently undertook clinical trials assessing the utility of rituximab and IVIG as desensitization agents.

Dr Jordan has published more than 400 peer-reviewed manuscripts and has 14 patent applications (two awarded and 7 licensed). He has been recognized by his peers with many awards, including the National Kidney Foundation "Gift of Life Award" and the Distinguished Alumni Award from the University of North Carolina Chapel Hill. He has been honored many times, including the inaugural Cedars-Sinai Prize for Research in Scientific Medicine (PRISM), the Pioneer in Medicine Award from Cedars-Sinai, the Award for Outstanding Achievement in Transplantation, and the Jean Hamburger Award. Most recently, Dr Jordan received the Medawar Prize from the Transplantation Society and the prestigious Paul Terasaki Clinical Sciences Award from the American Society of Histocompatibility and Immunogenetics.